

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.

Nanologica Publishes Prospectus in Connection with Rights Issue

Nanologica AB (publ) ("Nanologica" or the "Company") publishes a prospectus in connection with the rights issue of units corresponding to approximately SEK 99.4 million that was resolved by the board of directors on August 29, 2024 and that was approved by the extraordinary general meeting on September 23, 2024 (the "Rights Issue").

Prospectus

The prospectus has been prepared in connection to the Rights Issue and has today, on September 26, 2024, been approved by the Swedish Financial Supervisory Authority. The prospectus, which contains complete terms and conditions for the Rights Issue, is available on the Company's website (www.nanologica.com). The prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). Subscription forms will be available on the [Company's](#) and Bergs Securities AB's respective websites.

Timetable for the Rights Issue

30 September - 14 October 2024	Subscription period
30 September - 9 October 2024	Trading in unit rights
30 September - 30 October 2024	Trading in BTU
16 October 2024	Estimated day for announcement of the outcome of the Rights Issue

Advisors

Nanologica has engaged Redeye AB as Joint Bookrunner, Bergs Securities AB as Joint Bookrunner and issuing agent, and Advokatfirman Lindahl KB as legal advisor in connection with the Rights Issue.

For further information, please contact

Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Attachments

[Nanologica Publishes Prospectus in Connection with Rights Issue
Prospekt, Nanologica AB \(publ\), 2024 09 26 Final](#)